哈洛泽生物 HALO

Dr Torley , She has served as Chief Executive Officer (CEO) of Halozyme since 2014, successfully leading the company through a critical strategic transition in 2019. Dr Torley previously served as Chief Commercial Officer at Onyx Pharmaceuticals from 2011-2013, leading the successful US launch for Kyprolis (Carfilzomib), until the acquisition of Onyx by Amgen in 2013. From 2002-2011 Dr Torley held several senior commercial positions at Amgen including Vice President and General Manager US Bone Health and Vice President and General Manager US Nephrology. In these positions she led the successful launches of Prolia (denosumab) and Sensipar (cinacalcet) and significantly grew Epogen (Epoetin alfa) and Aranesp (darbepoetin alfa) revenue. From 1997-2002 she held a range of senior sales and marketing leadership positions at Bristol Myers Squib. She began her industry career at Sandoz, which merged with Ciba-Geigy to become Novartis in 1996, where she held a range of positions of increasing responsibility in Clinical Development, culminating in the position of Vice President of Medical Affairs, responsible for overseeing the design and conduct of a broad portfolio of clinical studies across nephrology, rheumatology, oncology and CNS indications. She received her M.B.Ch.B. degree (US equivalent to MD) from the University of Glasgow, Scotland and her M.R.C.P from the Royal College of Physicians, Glasgow, Scotland. As CEO of Halozyme, Dr. Torley has gained experience in Finance and Capital Markets including direct experience with raising over $1.5 billion through follow-on offerings and through three convertible debt offerings, and executing three share repurchase programs resulting in approximately $1.55 billion in capital returned to stockholders to date. During her time at Amgen, Onyx and Halozyme, she has been involved with and has led the identification and evaluation of multiple acquisition opportunities, and the execution of several acquisitions including Halozyme's acquisition of three companies during her tenure as our chief executive officer. Recent Past Public Company Board Experience: Quest Diagnostics Incorporated, a diagnostic information services company.

Mark Snyder (59), Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder joined Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder has over 33 years of experience in legal and business management roles. Prior to joining Halozyme, from January 2008 to December 2021, Mr. Snyder served in various senior positions in the legal department at Qualcomm Incorporated, a wireless communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation, from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm, Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and has held legal and business management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney at the law firm of Sheridan Ross & McIntosh. Mr. Snyder received his B.S. degree in chemical engineering at the University of Rochester and his M.B.A. degree from Boston College Carroll School of Business. He received his J.D. from Boston College Law School.

Mr. Henderson ,He has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previously served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in August 2015. From 1998 to 2005, Mr. Henderson held various senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Business Administration and he has completed the NACD/Carnegie Mellon University CERT Certificate in Cyber-Risk Oversight program for governance professionals. In his almost 15 years experience as Chief Financial Officer at Cardinal Health and Controller/Treasurer at Eli Lilly, Mr. Henderson gained extensive experience in finance and capital markets. During his tenure at Cardinal Health, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographic locations and market segments. During his time with the PE firm of Berkshire Partners, he was involved in the identification, evaluation and execution of multiple acquisition opportunities in the healthcare sector. Other Current Public Company Boards: Becton Dickinson and Company, a medical technology company Qualcomm, Inc., a wireless communications and semiconductor company.

Ms. Connaughton , From 2004 to October, 2017, she served in senior management position at Bristol-Myers Squibb Pharmaceutical Company, most recently served as president, China, Latin America, Central and Eastern Europe and Middle East. In this position, she developed the multi-year strategy for the successful commercialization of a number of oncology, virology and immunology products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia. Prior to serving in that role, Ms. Connaughton served as Bristol-Myers Squibb's president, European Markets, Canada and Australia; president, Intercontinental; and president, Japan, Pacific Rim, Australia and Canada; senior vice president, Cardiovascular and Metabolic Business Unit, U.S.; and senior vice president, Primary Care Marketing, U.S. Ms. Connaughton also served on the European Federation of Pharmaceutical Industry Association, Patient Access and European Markets Committees from 2014 to 2016. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania. Other Current Public Company Boards: Editas Medicine, Inc., a clinical stage biotechnology company. Recent Past Public Company Board Experience: Syneos Health Inc., a biopharmaceutical services company; Zealand Pharma A/S, a biotechnology company (term ends on March 26, 2026).

Mahesh Krishnan, M.D.,Since 2009, Dr. Krishnan has served in various roles at DaVita, Inc., a provider of kidney dialysis services, including service as the co-lead of DaVita Venture Group, the external innovation arm of DaVita, Inc., where he is responsible for strategic partnerships in technology and research and development at DaVita, as well as medical policy in Washington, D.C. Since May 2019, Dr. Krishnan has also served as DaVita's Group Vice President of Research and Development and prior to that role, Dr. Krishnan served as DaVita's first international Chief Medical Officer from 2015 to May 2019. From 2004 to 2009, Dr. Krishnan served in various roles at Amgen Inc., a multinational biopharmaceutical company, including serving as the Global Development Leader for Epogen and as Executive Director, Medical Policy for all of Amgen's domestic products. From 2000 to 2004, Dr. Krishnan was a practicing nephrologist at Virginia Nephrology Group. He earned his M.D. from Jefferson Medical College at Thomas Jefferson University and his B.S. in pre-medicine from The Pennsylvania State University. He also holds an M.P.H. from Johns Hopkins University and an M.B.A. in health care management from the Johns Hopkins Carey School of Business. Dr. Krishnan served as a practicing nephrologist at Virginia Nephrology Group where he managed daily operations. While at Amgen, he oversaw clinical trial execution for Epogen and served as the executive director for medical policy and as the executive director for medical affairs. He also served as Vice President, Clinical Research and Publishing, Vice President Clinical Innovation and Public Policy and as Founding International Chief Medical Officer for DaVita during which time he was involved in a wide variety of operational and commercial functions for a premier nephrology health services company. As a Chief Medical Officer for DaVita he gained extensive experience in multi-site and international medical services delivery. Dr. Krishan gained extensive experience in pharma business leadership and operations in his role as executive director, medical affairs at Amgen. While at Amgen, he developed and executed on the medical affairs and marketing plan for Epogen and negotiated multiple label iterations with the United States (U.S.) Food and Drug Administration (FDA). As global development leader for Epogen he also oversaw multiple aspects of the FDA regulatory advisory committee meetings and successfully implemented a large molecule manufacturing change clinical program. At DaVita, Dr. Krishnan served as the international chief medical officer and oversaw clinical, operational and safety performance for DaVita's clinical healthcare operations in eleven countries. Dr. Krishnan has also authored two books on pharmaceutical sales training. Dr. Krishnan currently serves as group vice president of DaVita Venture Group. Recent Past Public Company Board Experience: Chinook Therapeutics, Inc

Mr. Lang From May 2017 to August 2025, he served as founder and chief executive officer of EVERSANA, a provider of global commercialization services for the life sciences industry. Since December 2016, Mr. Lang has also served as an executive advisor to Water Street Healthcare Partners, a strategic private equity firm focused exclusively on building market-leading companies in healthcare. From 2012 to 2016, Mr. Lang served in leadership roles at Decision Resources Group, a multi-national corporation that provides high value global data solutions, analytics, and consulting services to pharmaceutical, biotech, medical device, healthcare provider and payer, and managed care companies, including as its Chief Executive Officer from 2014 to 2016. From 2006 to 2008, he served as President of IHS Cambridge Energy Research Associates, an international research and consulting firm, which delivered strategic knowledge and independent analysis on energy markets, geopolitics, industry trends, and strategy. From 1989 to 2006, he held various roles at Strategic Decisions Group (SDG), a global strategy consulting firm, including as President and Chief Operating Officer from 2000 to 2006. Mr. Lang received his BS in electrical and computer engineering from the University of New Hampshire and his MBA from the Tuck School of Business. As the founder and former chief executive officer of EVERSANA, Mr. Lang gained extensive experience leading a company that provides global commercialization services for the life sciences industry. EVERSANA solutions are rooted in the patient experience, a key focus for Halozyme, and span all stages of the product life cycle to deliver sustainable value for patients, prescribers, channel partners and payers. EVERSANA serves more than 650 life science organizations, including start-up and established pharmaceutical companies to advance life sciences solutions. Mr. Lang also currently serves as an executive advisor to a strategic private equity firm focused exclusively on building market-leading companies in the healthcare industry. Other Current Public Company Boards: BioVie, Inc., a clinical stage biopharmaceutical company OptimizeRX Corporation, a digital healthcare technology company

On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. .Mr. Daly previously served on Halozyme's Board of Directors and has held senior commercial leadership roles across leading global biopharmaceutical companies. He served as Executive Vice President and Chief Commercial Officer of Incyte Corporation from 2012 to 2015. Prior to Incyte, he spent a decade at Amgen, where he held senior commercial leadership positions, including his most recent role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, Mr. Daly spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, where he held positions of increasing responsibility, including Senior Vice President and General Manager of the U.S. respiratory business. Mr. Daly currently serves on the boards of Acadia Pharmaceuticals, Madrigal Pharmaceuticals and Cytokinetics. He previously served on the boards of argenx, Bellicum Pharmaceuticals and Chimerix. He holds a Bachelor of Science in Pharmacy and an M.B.A. from the University at Buffalo, State University of New York.

On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc.

Effective June 8, 2026, Darren Snellgrove has been appointed as the Chief Financial Officer (CFO). Mr. Snellgrove brings more than 30 years of exceptional financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson, a Fortune 50 healthcare company. In that role, he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance. Previously, Mr. Snellgrove served as Chief Financial Officer of Johnson & Johnson's Pharmaceuticals sector, where he provided global financial leadership for a business generating more than $50 billion in annual revenue. During his tenure, he delivered impressive financial results, leading large global teams across commercial operations, R&D, supply chain, and business development, and played a central role in major portfolio investments, restructuring initiatives, and business development transactions. Earlier in his career, Mr. Snellgrove held CFO and senior finance leadership roles across pharmaceutical R&D, innovation, and M&A at Johnson & Johnson, as well as progressive finance roles at Centocor before its acquisition. Mr. Snellgrove holds a B.A. Honors Degree in Economics and Philosophy from Southampton University, England, and an M.B.A. from Villanova University.